Ranolazine
- Generic Name
- Ranolazine
- Brand Names
- Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H33N3O4
- CAS Number
- 95635-55-5
- Unique Ingredient Identifier
- A6IEZ5M406
- Background
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drug...
- Indication
Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
...
- Associated Conditions
- Chronic Angina, Ventricular Arrhythmia
- Associated Therapies
- -
Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities
- Conditions
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- William Beaumont Hospitals
- Target Recruit Count
- 29
- Registration Number
- NCT00914316
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
- Conditions
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 5
- Registration Number
- NCT00832572
- Locations
- 🇺🇸
Cardiovascular Institute of the South Clinical Research Corporation, Houma, Louisiana, United States
Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Colorado Prevention Center
- Registration Number
- NCT00657514
- Locations
- 🇺🇸
University of Colorado at Denver, Aurora, Colorado, United States
🇺🇸Denver Health and Hospital Authority (DHHA), Denver, Colorado, United States
🇺🇸Department of Veteran Affairs Medical Center, Denver, Colorado, United States
An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
- Conditions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 172
- Registration Number
- NCT00644332
- Locations
- 🇺🇸
Total Heart Care, PC, New York, New York, United States
🇺🇸South Denver Cardiology Associates, PC, Littleton, Colorado, United States
🇺🇸Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 14
- Registration Number
- NCT00574756
- Locations
- 🇺🇸
UCSD Medical Center, San Diego, California, United States
Microvascular Coronary Disease In Women: Impact Of Ranolazine
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00570089
- Locations
- 🇺🇸
AHSP, Los Angeles, California, United States
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
- First Posted Date
- 2004-12-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6560
- Registration Number
- NCT00099788
- Locations
- 🇺🇸
The TIMI Study Group, Boston, Massachusetts, United States
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
- Conditions
- First Posted Date
- 2004-09-10
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT00091429
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.